

# Keyword Index

5-hydroxymethylation	B032
<b>A</b>	
abdominal cancers	B034
adenocarcinoma of colon	B034
adherence	A027
advance cancer	PR011
advanced stage melanoma	B010
advanced thyroid carcinoma	B024
aflatoxin B1	B034
anal cancer	B018
analytical validation	A012
anaplastic large cell lymphoma	A074
ancestry	A066
aneuploidy	IA021
anti-PD1	PR018, B052
aqueous humor	A062
aqueous humor liquid biopsy	B030
artificial intelligence	IA021
autoencoder	B053
<b>B</b>	
B7H3 immunotherapy	PR014
biobank	A013
bioinformatics pipeline	B063
biomarker	PR017, A011, A015, A021, A034, A035, A036, A053, A058, B021, B051
biomarkers of immunotherapy response	B046
bisulfite sequencing	B065
bladder cancer	B040
bladder cancer surveillance	A072
blood-based screening	A027
brain tumors	PR014
breast cancer	B005, B013, B014, B072, B074
breast cancers	A006
breast neoplasm	B070
<b>C</b>	
caffeine	B072
cancer	A021

cancer biomarkers	B061, B062
cancer detection	A057
cell surface proteins	B042
cell surface proteolysis	A059
cell-circuit	A029
cell-free DNA (cfDNA)	IA007, IA025, PR011, A036, A042, A060, B005, B023, B027, B044, B049, B063, B065, B068
cell-free DNA fragments	PR020, B060
cell-free RNA	A023
cerebrospinal fluid	B043, B071
cerebrospinal fluid liquid biopsies	B012
cervical cancer	A012, A065
cfMeDIP-seq	PR004, B004
cfRNA	A039
cfRNA extraction	A020
chemoresistance	B070
chemotherapy	A025
chromatin	PR016, B067
circulating cancer-associated fibroblasts	A004
circulating tumor cells (CTCs)	IA004, IA005, PR001, PR005, PR010, A001, A003, A004, A005, A006, A017, A031, A033, A036, A038, A047, B010, B014, B026, B041, B042, B066
circulating tumor DNA (ctDNA)	IA017, IA024, PR003, PR007, PR015, A025, A037, A048, B001, B011, B019, B027, B029, B035, B039, B059
cirrhosis	A068
clonal hematopoiesis	B064
colon cancer	IA017
colorectal cancer	PR009, PR013, A011, A027, A063, B038
colorectal cancer assay	A024
comparative oncology	B003
computational genomics	B054
cost-effectiveness	A061
CRC	B011
CRISPR	A014
ctHPVDNA	A007
cystic fluid and serum biopsy	B037
<b>D</b>	
DDLPS	A054
ddPCR	A026
diagnostic	A060
diagnostics	A047

differential methylation	B063
diffuse large B-cell lymphoma	A051
DNA methylation	IA025, A015, B013
DNA methylation-based brain tumor classification	B012
dogs	A051
double positive circulating tumor cell	A003
ductal carcinoma in situ	IA004

## E

early breast cancer detection	A044
early colorectal cancer detection	A045
early detection	A050, A075
early dissemination	IA004
early gastric carcinoma detection	B075
electrochemical sensor	A030
endpoint	B006
enhancers	IA025
epigenetics	IA005, PR017, B002, B051, B054, B068
epigenome	PR020, B060
epigenomics	PR011, PR012, A057, B035
epitranscriptome	A039
erythrocytes	A041, B073
esophageal adenocarcinoma	PR003, B001
Ethiopia	B074
exosomal diagnostics	B003
exosome	PR013, A063
extracellular vesicles	A009, A011, A016, A028, B003, B017, B048

## F

fibrosis	A068
fixation effect	A013
fragmentome	A050, B025
fragmentomics	PR008, B016, B044, B054, B058, B068
FTIR/Raman spectroscopy	A010

## G

gamma delta T cells	A008
gastroesophageal cancer	A049
gastrointestinal cancers	A041
gene hypermethylation	A026
genomics	B030
glioblastoma	B069
glioblastoma multiforme	B026

glioma	B021
H	
HCC	A050
head and neck	A043
head and neck cancer	IA018, PR004, A010, B004, B023, B048, B056
head and neck squamous cell carcinoma	B031
hematuria	A071
hepatocellular carcinoma	B073
HER2	A046
HER2-low	A001
HER2-ultralow	A001
hereditary tumor	B008
high volume	A042
high-throughput microfluidic device	A017
HPV	IA018
HPV cancer	PR007, A048
HPV16 E7 protein	A065
human papillomavirus (HPV)	PR002, A002, A019, B023
hypermethylation	B036
hypoxia	A047
I	
IL-10R2/IL-22R1	A058
immune biomarkers	A008
immune cell composition	B031
immune cells	A057
immune repertoire sequencing	A008
immunotherapy	PR008, B016, B047, B048
interception	A066
intrinsic subtypes	B074
IO therapy	PR015
K	
KRAS G12V mutation	A020
L	
large oncosomes	IA011
leptomeningeal metastatic disease	B043
liquid biopsy	IA011, PR012, A009, A020, A022, A024, A049, B009, B011, B013, B017, B026, B033, B045, B049, B057, B061, B062
liquid biopsy-RECIST	PR009, B038

long non-coding RNA biomarker	A067
longitudinal disease monitoring	PR014, B012
long-read sequencing	A023
lung cancer	A075, B058
lung cancer screening	A064
lung cancer screening adherence	A064
lymphoma	B020
M	
machine learning	IA021, IA026, A010, A067, B053, B056, B058
magnetophoresis	A029
MALDI-ToF	A032
mass cytometry	PR005, A033
matrix metalloproteinase	A028
mDETECT	B050
MDM2 variants	A054
MDM2-ALT2	A054
melanoma	PR018, B044, B047, B052
melanoma metastasis/MBM	PR001
mesothelioma	A060
metabolic dysfunction-associated steatotic liver disease	A068
metastatic solid tumor	A005
methylation	A014, A035, A053, A062, B005, B050
microfluidic	A030
micronuclei DNA	A041, A045, B073, B075
microRNA	A021
minimal residual disease (MRD)	IA007, IA017, A022, A022, A043, B006, B007, B027, B029, B032, B057
minimal residual disease (MRD) monitoring	B009
modeling	PR006, A073
molecular residual disease	IA018, B022, B028
molecular response	PR009, B020, B038
monitoring	PR008, PR015, B016, B025
mortality	PR006, A073
mtDNA	A040
multi-analyte	A075
multi-biomarker class reflex testing	A056
multi-cancer early detection	PR006, A056, A073
multi-cancer early detection (MCED)	A061
multi-cancer screening	PR019, B055
multiomics	IA011
multi-omics	A009, B020

multiple myeloma	B006, B007, B032
multiplex lateral flow assay	A074
multiplexed imaging	A031
mutations	B040
mutli-cancer early detection	A064
N	
neoadjuvant therapy	B019
network pharmacology	B072
next-generation sequencing	A037, B043
noise suppression	B057
non-Hodgkin lymphoma	B017
non-small cell lung cancer	A025, B045, B046, B050
normal muscle reprogramming	A055
nucleosome occupancy	B053
nucleosome profiling	B040
O	
Oncuria®	A069
Oncuria®-Detect	A070, A071
Oncuria®-Monitor	A072
organoids	A006
oropharyngeal cancer	A007, B022
oropharyngeal squamous cell carcinoma (OPSCC)	A019
osimertinib	B036
osteosarcoma	A028
P	
pancreatic cancer	A016, B037
pancreatic carcinoma	A059
pancreatic ductal adenocarcinoma	A058
Parsortix®	A038, A046
pathways	B036
PDAC	A040
PD-L1	A030, A038
pediatric	B039
pediatric brain tumors	B071
pediatric cancer	IA024
pediatric renal tumors	A026
performance	A056
peritoneal tumor DNA	A049
personalized panel	B009
plasma	A016, A019, A032, A034

plasma based assays	B064
preanalytics	A024
precision diagnostics	A031
predictive biomarker	B002
priming agents	IA007
prognosis	IA024
prognostic biomarker	B037
prognostic biomarker identification	A067
prognostic marker	B010
prognostic stratification	A052
prostate	B066
prostate cancer	IA005, PR010, B002, B041, B062
proteomics	PR013, PR018, A032, A034, A063, B052
Q	
qPCR	A035
qualitative research study	B007
quantum sensing	B033
R	
radiotherapy	B014
Raman spectroscopy	B056
recurrence detection	B018
renal cell carcinoma	A052
residual cancer burden	B019
resistance mechanisms	B015
retinoblastoma	A062, B030
risk assessment	A066
risk stratification	A051
risk-stratifying biomarker	B008
RNA liquid biopsy	A023
RNA modification	A039
RNA sequencing	PR010, B041, B042
S	
saliva and blood	B061
samples integrity	A013
screening early detection	PR007, A048
sequencing accuracy	A037
serial monitoring	B015
serum biomarker	A059
signature analysis	PR020, B060
simulated cancer	B065
single cell sequencing	A017

single nucleotide variants	IA021
single-cell CTC isolation	A029
single-cell proteomics	B069
size of circulating tumor cell	PR002, A002
solid tumor	B028, B039
soluble CD30	A074
squamous cell carcinoma	B045
surgical drain fluid	B031
T	
targeted therapy	B015
T-cells	PR017, B051
tdEV	A040
the RPL/RPS gene signature	PR001
therapy monitoring	B033
therapy resistance	PR005, A033
thyroid cancer	B024
tissue of origin classification	PR019, B055
transfer learning	PR019, B055
transformed cells	A065
transoral robotic surgery	A007
tRCC	B035
treatment monitoring	B047
triple-negative breast cancer (TNBC)	A053, B008
tRNA-derived fragments (tRFs)	B021
tumor fraction	B059
tumor invasive clusters	A055
tumor methylation profiling	B046
tumor microenvironment	B069
tumor muscle invasion	A055
tumor phenotype classification	IA026
tumor subtyping	IA026
tumor tissue modified viral (TTMV)-HPV DNA	A012, B018, B022
tumor-associated micronuclei DNA	A044
tumor-informed ctDNA	B024
tumor-informed whole genome sequencing	B028
two-step approach	A061
U	
upper tract urothelial tumors	A070
urine	A042, A070, A071, A072
urine sample storage	A069
urologic malignancy	B064



V	
validation	B066
VEGFA	A005
W	
whole genome sequencing (WGS)	A043, B025, B029
whole methylome	PR004, B004
X	
xenograft	A052